Interpretive Risk Review™—An Independent Expert Review of Consumer Interpretation Risk in Health Communications
IRR identifies where patient-facing and consumer-facing health communications may be misinterpreted by non-professional audiences.
More- Telehealth companies
- Pharma & biotech companies
- Direct-to-consumer health brands
- GLP-1 / weight loss companies
- Health plans and Health Plan marketers
- Medical device companies
- AI-generated health content developers
FTC and FDA enforcement increasingly focuses on how consumers understand and interpret health communications
Technically accurate, legally reviewed health communications can still create problematic impressions for the audiences who receive them. In the current regulatory environment, that gap is no longer theoretical.
Scrutiny of consumer-facing health claims
Recent FDA enforcement reflects heightened attention to whether patient-facing communications create accurate impressions among non-professional audiences — not merely whether they state accurate facts.
The net impression standard
FTC's deception framework focuses on what a consumer takes away from a communication — not only what a communicator intended or what legal review approved. Technical accuracy does not resolve interpretive risk.
Accelerated surveillance and scrutiny
Automated monitoring tools have shortened the time between publication and regulatory attention. The cost of identifying a comprehension gap after materials go live is materially higher than doing so before.
Risk is best addressed before it materializes
IRR is designed for use before materials are published, filed, or escalated — when identifying interpretive risk is least disruptive and the window for revision is still open.
A Distinct Form of Expert Review
IRR is an independent expert assessment of how health communications are likely to be understood by non-professional audiences. Advisory in nature, upstream in timing, and designed to surface interpretive risk early in the communications process.
What IRR Reviews — A Consumer Lens
IRR reviews patient- and consumer-facing health communications to identify where messaging may be understood in ways that diverge from clinical, regulatory, or legal intent.
The focus is on wording, framing, structure, sequencing, and omission—the elements that shape what a non-professional audience is likely to take away, regardless of what the content was designed to communicate.
This includes website copy, advertising, onboarding flows, pricing language, patient education materials, drug and device communications, and AI-generated health content.
IRR complements, but does not replace, legal or regulatory review. Its value lies in adding what those disciplines are not designed to provide — an independent read on how communications are likely to be misinterpreted by the consumers they reach.Not a Substitute for Legal Review
Legal review asks whether materials comply with applicable law and regulation. IRR asks a different question: what is a non-professional consumer likely to understand this communication to mean?
Both questions matter. But they are separate inquiries, addressed by different expertise. IRR is not a legal opinion or regulatory determination. It is an expert assessment of the interpretive risk that technically accurate and legally reviewed communications may still carry.
Designed for legal and regulated health audiences
IRR serves organizations whose communications with non-professional audiences carry interpretive risk — and where the question of consumer understanding is distinct from that content's legal and regulatory compliance.
Law Firms
FDA regulatory counsel, advertising law practices, and litigation support teams advising clients on consumer-facing health claims and materials where interpretive risk is a factor.
- Pre-publication review of client DTC health materials
- Regulatory inquiry and enforcement contexts where consumer understanding is at issue
- Litigation support on consumer understanding questions
Telehealth Companies
Organizations in high-scrutiny categories — GLP-1 programs, mental health platforms, chronic condition management — where consumer communications carry elevated interpretive risk.
- Website and onboarding copy in regulated service categories
- Drug and treatment communications where efficacy or outcome language reaches consumer audiences
- Pricing and subscription communications
Pharmaceutical & Biotech
Teams preparing direct-to-consumer advertising, patient education, product labeling supplements, and consumer communications in regulated markets.
- DTC advertising and consumer-facing communications
- Patient education materials and consumer-facing clinical communications
- Clinical trial recruitment communications
Direct-to-Consumer Health
Diagnostic, biomarker, genetic testing, and personalized health businesses communicating complex value propositions to general consumer audiences.
- Results and risk-language communications
- AI-assisted health recommendation communications
- Benefit and limitation disclosures in marketing
Employers & Health Plans
Organizations communicating benefit design, coverage options, and health programs to employee or member audiences where misunderstanding creates material exposure.
- Open enrollment and benefits election communications
- Coverage limitation and exclusion language
- Care navigation and program description materials
A structured, confidential advisory process
Each engagement is handled with discretion and designed to integrate into existing legal, regulatory, and compliance review cycles. Turnaround is calibrated to client timelines.
Submit Materials
Website copy, advertising, onboarding flows, pricing language, patient communications, product information, or AI-generated health content.
Independent Assessment
Expert review of where wording, framing, structure, sequencing, or omission may create inaccurate or unintended consumer impressions in the materials submitted.
Written Report
Prioritized findings tied to specific language, structure, or framing — with context explaining each interpretive gap identified.
Consultation
A focused discussion of findings and their interpretive implications within the context of your materials and risk environment.
IRR Report Review
One follow-up virtual meeting to discuss findings and address questions. Additional IRR review of revised materials is available upon request at additional cost.
Grounded in scientific expertise and communications judgment
IRR draws on decades of training and practice at the intersection of molecular science, public health, and consumer-facing communications — applied to the specific problem of interpretive risk in regulated health contexts.
Independent Expert Judgment
An outside perspective free from the assumptions embedded in how materials were drafted or approved internally. IRR focuses on what a non-professional audience is likely to understand — not what was intended, and not what legal review addressed.
Scientific and Communications Depth
Doctoral training in molecular genetics combined with three decades of applied experience in public health communications, patient education, and consumer-facing health information programs. The combination is not common. The risk it addresses is.
Upstream Risk Orientation
IRR is most valuable before materials are finalized, submitted, or published — when identifying interpretive risk is least disruptive and the cost of addressing it is lowest. It is designed as a proactive advisory tool — engaged earliest when its value is highest.
Led by Dr. Mary S. Harris, PhD
Dr. Harris brings a rare combination of doctoral scientific training, deep expertise in public health communications, and three decades of practical judgment about how health information is understood — and misunderstood — by general audiences in high-stakes settings.
Her background spans research, advisory, and communications contexts at the intersection of the life sciences and public-facing health information. Interpretive Risk draws directly on that experience, applied to the specific challenge of interpretive risk in consumer-facing health communications.
Common questions about IRR
These questions reflect what clients typically ask before or at initial consultation. Additional questions are answered below.
What is Interpretive Risk Review™?
An independent expert assessment of how patient-facing and consumer-facing health communications are likely to be understood by non-professional audiences — and where that understanding may diverge from what the communication was clinically or scientifically intended to convey.
How is IRR different from legal review?
Legal review asks whether materials comply with applicable law and regulation. IRR asks what a non-professional consumer is likely to understand the communication to mean. Those are different questions, addressed by different expertise. IRR complements legal review but does not replace it.
Who typically requests IRR?
Law firms and regulatory counsel, telehealth companies, pharmaceutical and biotech teams, direct-to-consumer health platforms, and employers or plans — in each case where interpretive risk in consumer-facing health communications is a material concern.
What materials can be reviewed?
Website copy, onboarding materials, advertising, patient education, pricing and benefit language, product communications, clinical trial recruitment materials, and AI-generated health content — across any channel where non-professional audiences are the primary recipients.
Request a Consultation
Interpretive Risk works with law firms, regulatory counsel, and health organizations on a direct inquiry and referral basis. Initial consultations are focused and confidential.
Engagements can be structured to integrate with existing legal and compliance review workflows. Confidential engagements are available.
Interpretive Risk Review™ is a professional consulting service and does not constitute legal advice, regulatory opinion, or legal representation.
Send an Inquiry
Submission of this form does not create a professional relationship. All inquiries are handled in strict confidence.